| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
10 |
/ |
2021 |
|
|
|
| |
Data sporządzenia: |
2021-04-01 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
The Update on Commercial Rollout of CompuFlo® Epidural System and CathCheck™ System |
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_
today provided the update on the commercial rollout of CompuFlo Epidural System and
CathCheck™ System.
The Board of Directors of the Issuer is pleased to report that the Company has made
significant progress over the past year advancing its commercial efforts around the
CompuFlo® Epidural Instrument and CathCheck™ System. Specifically, the Company has
added new distributors and begun to penetrate key hospitals with our CompuFlo® Epidural
Instrument and the Issuer expects this trend to continue as we anticipate adding additional
hospitals in 2021. A key element of the sales strategy focuses on the disposable components
of its system, which the Board of Directors of the Issuer believes will contribute
to high margins and recurring revenue. The Company is also expanding its medical sales
force, and now that new protocols are in place at hospitals, the Issuer is better
able to enter the hospitals and has commenced a number of new pilot programs. Overall,
the response from both hospitals and physicians has been positive and the Company
is in a number of trials across the country that have the potential to convert to
additional commercial orders this year.
Given a strong cash runway of its parent, The Board of Directors of the Issuer believes
that the Company is well funded to accelerate the sales and marketing activities around
the medical instruments. The Board of Directors of the Company believes that the strength
of our balance sheet of its parent provides the substantial runway to advance the
development and commercialization of other indications for our proprietary DPS Dynamic
Pressure Sensing Technology. The Board of Directors of the Company believes this
technology platform is quite broad with multiple indications in large and underserved
markets.
|
|
|
RB_ASO: The Update on Commercial Rollout of CompuFlo® Epidural System and CathCheck™ System
